drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous gene-modified CAR T cells)
drug_description
Autologous patient T cells genetically engineered to express a chimeric antigen receptor targeting the EX02 antigen on AML blasts; upon binding, CAR signaling (CD3ζ/costimulatory domains) activates T cells to release cytokines and mediate perforin/granzyme-dependent cytotoxicity, with in vivo expansion and persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds the EX02 antigen on AML blasts. CAR engagement triggers CD3ζ and costimulatory signaling to activate the T cells, leading to cytokine release, proliferation/expansion, and perforin/granzyme-mediated cytotoxic killing of EX02-positive leukemia cells, with persistence in vivo.
drug_name
EX02 CAR-T cells
nct_id_drug_ref
NCT06642025